ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Inclusion Criteria

• Adults ≥18 years of age.
• ECOG performance status 0 or 1.
• Estimated life expectancy of more than 12 weeks .
• Patients with advanced or metastatic solid tumors, confirmed by histologically or pathologically documented, who have progressed after all standard therapies, or for whom no further standard therapy exists.
• At least 1 measurable lesion at baseline according to the definition of RECIST v1.1.
• Adequate organ function.
• Meets the additional tumor type requirements as specified in Protocol.

Exclusion Criteria

• Treatment with any investigational drug within washout period.
• Major trauma or major surgery within 4 weeks prior to first dose of study drug(s)
• History of significant immune-mediated AE.
• Central nervous system (CNS) disease involvement.
• Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC)/bone marrow (BM) transplantation
• Clinically significant cardiac disease.
• Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
• Patients who received:
• A COVID-19 vaccine within 7 days of Cycle 1 Day 1.
• Live vaccines or live-attenuated vaccines within 28 days prior to Cycle 1 Day
• 9. Known active infection of HBV/BCV/HIV.
• Patients requiring systemic treatment with corticosteroids or other immunosuppressive medications (>10 mg/day prednisone or equivalent).
• Second primary malignancy not in remission for greater than 3 years.
• History(within the last 5 years) or risk of autoimmune disease.
• Pregnant or breastfeeding females.
• Childbearing potential who does not agree to the use of contraception during the treatment period.